A biopharmaceutical company developing innovative therapeutics in the fields of oncology and infecti

1
A biopharmaceutical company developing innovative
therapeutics in the fields of oncology and
infectious diseases (TSXAMB) 0
Corporate Presentation Last update April 24, 2007
2
This presentation contains forward-looking
statements that reflect the Companys current
expectation regarding future events. The
forward-looking statements involve risks and
uncertainties. Actual events could differ
materially from those projected herein and depend
on a number of factors including, but not limited
to, changing market conditions, successful and
timely completion of clinical studies,
uncertainties related to the regulatory approval
process, establishment of corporate alliances and
other risks detailed from time to time in the
Companys filings. Such statements are also based
on various assumptions, including the successful
and timely completion of clinical studies on
Ambrilias products demonstrating efficacy and
safety for human use, their successful
commercialization within the forecasted timelines
and the attainment of the forecasted milestone
payments and other revenues. While Ambrilia
anticipates that subsequent events and
developments may cause Ambrilias views to
change, Ambrilia specifically disclaims any
obligation to update these forward-looking
statements.
Ambrilias Forward-Looking Statements
3
Investment Highlights

• Lead HIV/AIDS proprietary product licensed to
  top pharma, Merck Co. for US17 million
  upfront, potential US212 million in milestones,
  and royalties.
• Near-term product revenue opportunities from two
  new formulations of existing drugs, Octreotide
  and Goserelin.
• 2 leading pharma companies as licensees, TEVA
  and Mallinckrodt, of improved formulation of
  Octreotide.

4
Pipeline Overview
5
Ambrilia Merck Licensing Agreement

• Terms
• Merck receives exclusive worldwide rights to
  Ambrilias HIV PI Program, incl. lead compound
  PPL-100
• Upfront licensing fee US 17M, additional
  potential milestones US 212M
• Royalties on future product sales
• Merck assumes all future development costs
• Potential additional payments and royalties on
  development and commercialization of each related
  compound

6
PPL-100 Market potential

• HIV/AIDS market(1) estimated to reach US 9
  billion at the projected
  time of launch of PPL-100 (2012)
• PIs a healthy 1/3 of the HIV/AIDS treatment
  options - Todays Market
  leader Abbotts Kaletra US 1.0 B(2)
• PPL-100 market share and revenues expected to be
  significant based on its competitive advantages
• Excellent safety and tolerability
• Favorable cross-resistance profile
• High genetic barrier
• Potential once or twice-a-day dosage, ritonavir
  free

• Decision Resource 2004 HIV Infectious Diseases
  Study 68, Frost Sullivan 2004 Strategic
  Analysis World HIV Market, 2006 DataMonitor -
  Pipeline Insight HIV
• Life Science Analytics Medtrack Database

7
PPL-100 Phase 1

• Phase 1 single dose escalation study in healthy
  volunteers

8
PPL-100 Next Steps

• Phase 1 repeat dosing study in healthy volunteers
  completed by Ambrilia
• Good safety profile only mild (grade 1)
  adverse events and
• no moderate or severe cardiovascular,
  lipidic or hepatic adverse
• events observed
• PK data support the potential for once or twice
  daily treatment,
• without ritonavir boosting, for a
  significant proportion of
• HIV/AIDS patients
• Merck has initiated formulation development
• Further development in patients will follow

9
Near-term product revenue opportunities from two
new formulations of existing drugs
10
Oncology Improved formulation of Octreotide

• Therapeutic alternative to Novartis
  SandostatinLAR
• (somatostatin analogue)
• Indicated for acromegaly and some digestive
  tumors
• 2006 Sandostatin sales(1) US 900M ( 4 ),
  over 70 for the LAR
• Three dosages of LAR 10, 20 and 30 mg per unit
• 30mg (over 50 of market) sells for US 2,830 per
  unit
• 13 injections needed per year ( US 25,000 to gt
  US 36,000)
• Ambrilias C2L Improved prolonged release (PR)
  formulation developed with patented technology
• Less expensive and easier to use because more
  stable product
• Less frequent injections (8 or 9 vs 13 per
  year)
• Manufactured in-house, cGMP compliant

• Novartis Annual Report 2006

11
Octreotide Development Program

• Limited Phase 3 clinical studies
• in Europe and in the U.S.
• 3 months activity 3 months safety follow-up
• Endpoints Surrogate marker (GH IGF-1 levels)
• Upcoming milestones
• Start of clinical studies in acromegaly patients
  ?
• Filing in Europe. H1/08
• Filing in the U.S. H2/08

12
Octreotide Marketing Strategy

• Ambrilia manufactures and will sell the finished
  product to its licensees, at contractually
  fixed price
• Licensing agreements concluded with leading
  companies worldwide
• Agreements have been concluded for
  commercialization and have already generated
  milestone payments
• Mallinckrodt (U.S.), TEVA (France, Germany,
  Benelux, Spain, Scandinavia), Archimedes Pharma
  (U.K.), Gerolymatos (Greece, Turkey, other
  countries), Kwidza Pharma (Austria), Pharmis
  (Portugal, Brazil)
• C2L to be promoted as improved PR formulation,
  with 3 advantages less expensive, easier to use
  because more stable product, less frequent
  injections (8 or 9 instead of 13 per year)

13
Oncology New formulation of Goserelin

• Potential first-to-market therapeutic alternative
  to Astra Zenecas Zoladex LP (LHRH
  analogue)
• Indicated for hormone-sensitive prostate cancer
• 3-month prolonged release formulation developed
  with patented technology
• Zoladex 2005 sales(1) US 1.0 B (9),
  primarily in Europe (70 for the 3 month
  formulation)

• Life Science Analytics Medtrack Database

14
Goserelin Development Plan

• Upcoming Milestones
• In house formulation optimization Ongoing
• Start of phase 1/2 study in hormone-
• sensitive prostate cancer patients 2007
• Out-licensing 2008

15
Proprietary products in cancer and
infectious diseases
16
Oncology PCK3145

• Therapeutic anti-cancer peptide
• Indicated for hormone-resistant prostate cancer,
  a condition with very poor prognosis.
• Studied in close to 50 patients
• Safe, well-tolerated
• Completed U.S. pilot study (Memorial Sloan
  Kettering Cancer Center, NYC)
• Improved dosing
• Study completed
• Safety confirmed, and
• Evidence suggesting clinical activity ( incl. PSA
  doubling time increased up to 5 fold in several
  patients)
• Development partnership discussions ongoing

17
PSP94 Test Novel Biomarker Assay

• A test to measure the plasma levels of PSP94, a
  
• powerful new prostate cancer prognosticator
• Confirmed diagnostic value in published study
  in patients with
• prostate cancer
• Confirmed prognostic value in patients with
  risk of recurrence
• The PSP94 kit can help
• Avoid biopsies in patients diagnosed with
  probable prostate cancer
• Follow-up patients in observation before
  deciding to treat
• Partnership negotiations ongoing

18
Oncology TVT (Tumor and tumor-vasculature
targeting) Platform

• NGR peptides-based targeted drug delivery
  technology that
• delivers anti-cancer drugs to the vasculature
  of solid tumors and
• surrounding tumor cells
• Technology consists of a carrier vesicle coated
  with a tumor homing peptide (NGR) which binds
  specifically to a receptor (CD13 isoform)
  exclusively expressed in newly formed tumor blood
  vessels as well as on the surface of some types
  of tumor cells
• The carrier is then internalized and releases the
  anti-cancer drug which, in turn, specifically
  damages the tumor vasculature and kills the tumor
• Targeted NGR peptide can be attached to the
  surface of
• liposomes or other nanoparticles loaded with a
  single or
• combination of anti-cancer agents
• Proof-of-concept with Doxorubicin (Dox)
• NGR targeted liposomal Dox with convincing
  results in animal solid tumors models

19
HIV Integrase Inhibitor Program

• Integrase Inhibitor is a platform for the
  treatment of HIV/AIDS
• Merck and Gilead have Integrase Inhibitor
  products in late-stage development for the
  treatment of HIV
• Ambrilia to utilize Integrase Inhibitor Program
  to develop drugs to treat HIV/AIDS
• Status Lead optimization
• Novel structures with potentially a new mechanism
  of action
• 12 months to a drug candidate

20
Financial Snapshot
21
Management Team
Stephen G. Sudovar Executive Chairman of the
Board and CEO Bonabes de Rougé, M.D. Senior
Executive Vice-President CSO Monique
Létourneau, M.Sc., CFA Executive Vice-President,
Finance CFO Chandra J. Panchal,
Ph.D. Executive V.-P., Business Development,
Licensing and IP Jinzi Wu, Ph.D. Vice-President.,
Preclinical Basic Research, Richard La Rue,
LL.L, D.D.N. Vice-President., Legal Affairs, HR
Corp. Secretary
22
Summary Upcoming Milestones

• 2007
• PPL-100 Out-licensing ?
• Octreotide - Start of clinical trials ?
• PCK 3145 - Clinical results (4 months
  exposure) ?
• PSP94 Assay Licensing
• Goserelin Start of clinical trials
• 2008
• Octreotide Regulatory filing worldwide
• Goserelin Out-licensing
• HIV Integrase Inhibitor Program Drug candidate

23
A biopharmaceutical company developing innovative
therapeutics in the fields of oncology and
infectious diseases (TSXAMB)
www.ambrilia.com